Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
AstraZeneca
Merck
Mallinckrodt

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Patent: 9,994,914

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,994,914
Title:Mutation in the epidermal growth factor receptor kinase domain
Abstract: A new in-frame deletion was found in exon 19 of the EGFR gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutation, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutation.
Inventor(s): Hoglund; Bryan (Pleasanton, CA), Jin; Janet (Foster City, CA), Li; Yan (Palo Alto, CA), Liu; Wei-Min (Dublin, CA)
Assignee: Roche Molecular Systems, Inc. (Pleasanton, CA)
Application Number:14/873,931
Patent Claims:see list of patent claims

Details for Patent 9,994,914

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Roche Molecular Systems, Inc. (Pleasanton, CA) 2034-10-09 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Roche Molecular Systems, Inc. (Pleasanton, CA) 2034-10-09 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Roche Molecular Systems, Inc. (Pleasanton, CA) 2034-10-09 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Roche Molecular Systems, Inc. (Pleasanton, CA) 2034-10-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
Merck
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.